Tesamorelin vs CJC-1295: What the Research Shows
Tesamorelin and CJC-1295 side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Tesamorelin if…
- you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[5]
- you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[15]
Consider CJC-1295 if…
- you want randomized human hormone data (hormone levels, not a clinical benefit): a single injection raised mean plasma GH 2- to 10-fold for 6 days or more[9]
What they have in common
- WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[2]
Spec comparison
Showing 7 of 13 fields where the two differ. Class, Category, PCAC vote, Jul 2026, WADA, Anti-doping detection, Evidence strength are the same or both unknown.
| Field | Tesamorelin | CJC-1295 |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Also called | tesa, Egrifta | CJC, mod GRF, GRF 1-29 |
| Category | Growth hormone | Growth hormone |
| FDA status | FDA approved (Egrifta) | Not FDA approved · research chemical |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption. | Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. |
| Anti-doping detection |
|
|
| Half-life | 11 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR) | No published half-life foundPubMed search, 11 Oct 2026 |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101 | Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683 |
| Human studies we summarised | 12 human (11 randomized or controlled) of 16 summarised | 4 human (1 randomized or controlled) of 7 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 2 mg, 5 mg, 10 mg, 20 mg | 2 mg, 5 mg, 10 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026) | Not in the letters we track |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Tesamorelin and CJC-1295 together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 15 results, 2 Oct 2026).
The approved GHRH analogue versus the long-acting experimental one
Tesamorelin's trials measured fat: in HIV-associated abdominal fat, visceral adipose tissue decreased by 15.2% with tesamorelin and increased by 5.0% with placebo.[15]
CJC-1295's human data is hormonal: a single injection raised GH and IGF-I for days. Those are hormone levels, not fat or muscle.[9]
In the tesamorelin trial, IGF-I increased by 81.0% with tesamorelin and decreased by 5.0% with placebo.[15]
In a tesamorelin extension study, visceral fat reaccumulated after treatment stopped.[17]
In GHRH-knockout mice, once-daily CJC-1295 was more effective than the same dose given every 48 or 72 hours. This is mouse data.[11]
Label, half-life and safety flags
The tesamorelin label gives a mean elimination half-life of 11 minutes in healthy subjects.[5]
In its human trial, CJC-1295 showed an estimated half-life of 5.8 to 8.1 days.[9]
The Egrifta label says the effects of prolonged IGF-1 elevation are unknown and tells prescribers to monitor IGF-1 levels.[5]
Serious adverse events FDA links to CJC-1295 on its compounding safety page include increased heart rate and a systemic vasodilatory reaction.[18]
WADA lists CJC-1295 and tesamorelin, with sermorelin, in the same GHRH-analogue entry.[2]
Of the two, only tesamorelin appears in Drugs@FDA, as the prescription product Egrifta.[19]
Common questions
Is tesamorelin better than CJC-1295?
Tesamorelin has trial data on visceral fat and an FDA-approved product. The CJC-1295 human data cited here are hormone-level studies.[15]
What is the difference between tesamorelin and CJC-1295?
The tesamorelin label gives a mean elimination half-life of 11 minutes in healthy subjects.[5]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
- 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
- 5EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
- 7Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
- 8The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
- 9Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
- 10Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
- 11Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
- 12PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
- 16PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 17Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.AIDS (London, England) · 2008PMID 18690162Accessed 2 Oct 2026
- 18Official web pageOfficial web page · web page
- 19Drugs@FDA (openFDA) search: active ingredient "tesamorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
Found an error? Report a correction.